Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery

Shan Wei, Yoshitoshi Kasuya, Masashi Yanagisawa, Sadao Kimura, Tomoh Masaki, Katsutoshi Goto

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Hydralazine relaxed porcine coronary artery strips in a concentration-dependent manner by distinct endothelium-dependent and endothelium-independent actions. With lower doses (≤ 10-6 M), the hydralazine-induced relaxation appears to be completely endothelium-dependent and we designed the present study to elucidate the mechanisms of this endothelium-dependent relaxation. Hydralazine (10-6 M)-induced endothelium-dependent relaxation was not affected by the presence of 10-5 M indomethacin, 10-3 M L-N(G)-nitro-arginine (L-NOARG) or 10-5 M haemoglobin, and was accompanied by accumulation of cGMP but not of cAMP in artery strips. There was a close time-dependent parallel relationship between endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine (10-6 M). The endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine showed much slower kinetics than those induced by ionomycin (10-7 M). Pretreatment of the strips with actinomycin D (10 μg/ml) significantly inhibited not the endothelium-dependent relaxation and accumulation of cGMP induced by ionomycin (10-7 M) but those induced by hydralazine (10-6 M). These results suggest that hydralazine induces endothelium-dependent vasorelaxation via the slow accumulation of cGMP in the strips. This does not occur through the release of nitric oxide or prostaglandin I2 but through immediate transcription and probably expression of a molecule in the endothelium.

Original languageEnglish (US)
Pages (from-to)307-314
Number of pages8
JournalEuropean Journal of Pharmacology
Volume321
Issue number3
DOIs
StatePublished - Mar 5 1997

Fingerprint

Hydralazine
Vasodilation
Endothelium
Coronary Vessels
Swine
Ionomycin
Hemoglobin M
Dactinomycin
Epoprostenol
Indomethacin
Arginine
Nitric Oxide
Arteries

Keywords

  • cGMP
  • Endothelium
  • Hydralazine
  • Relaxation

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery. / Wei, Shan; Kasuya, Yoshitoshi; Yanagisawa, Masashi; Kimura, Sadao; Masaki, Tomoh; Goto, Katsutoshi.

In: European Journal of Pharmacology, Vol. 321, No. 3, 05.03.1997, p. 307-314.

Research output: Contribution to journalArticle

Wei, Shan ; Kasuya, Yoshitoshi ; Yanagisawa, Masashi ; Kimura, Sadao ; Masaki, Tomoh ; Goto, Katsutoshi. / Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery. In: European Journal of Pharmacology. 1997 ; Vol. 321, No. 3. pp. 307-314.
@article{5d86963d435948bcae406c71b3142432,
title = "Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery",
abstract = "Hydralazine relaxed porcine coronary artery strips in a concentration-dependent manner by distinct endothelium-dependent and endothelium-independent actions. With lower doses (≤ 10-6 M), the hydralazine-induced relaxation appears to be completely endothelium-dependent and we designed the present study to elucidate the mechanisms of this endothelium-dependent relaxation. Hydralazine (10-6 M)-induced endothelium-dependent relaxation was not affected by the presence of 10-5 M indomethacin, 10-3 M L-N(G)-nitro-arginine (L-NOARG) or 10-5 M haemoglobin, and was accompanied by accumulation of cGMP but not of cAMP in artery strips. There was a close time-dependent parallel relationship between endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine (10-6 M). The endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine showed much slower kinetics than those induced by ionomycin (10-7 M). Pretreatment of the strips with actinomycin D (10 μg/ml) significantly inhibited not the endothelium-dependent relaxation and accumulation of cGMP induced by ionomycin (10-7 M) but those induced by hydralazine (10-6 M). These results suggest that hydralazine induces endothelium-dependent vasorelaxation via the slow accumulation of cGMP in the strips. This does not occur through the release of nitric oxide or prostaglandin I2 but through immediate transcription and probably expression of a molecule in the endothelium.",
keywords = "cGMP, Endothelium, Hydralazine, Relaxation",
author = "Shan Wei and Yoshitoshi Kasuya and Masashi Yanagisawa and Sadao Kimura and Tomoh Masaki and Katsutoshi Goto",
year = "1997",
month = "3",
day = "5",
doi = "10.1016/S0014-2999(96)00972-7",
language = "English (US)",
volume = "321",
pages = "307--314",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery

AU - Wei, Shan

AU - Kasuya, Yoshitoshi

AU - Yanagisawa, Masashi

AU - Kimura, Sadao

AU - Masaki, Tomoh

AU - Goto, Katsutoshi

PY - 1997/3/5

Y1 - 1997/3/5

N2 - Hydralazine relaxed porcine coronary artery strips in a concentration-dependent manner by distinct endothelium-dependent and endothelium-independent actions. With lower doses (≤ 10-6 M), the hydralazine-induced relaxation appears to be completely endothelium-dependent and we designed the present study to elucidate the mechanisms of this endothelium-dependent relaxation. Hydralazine (10-6 M)-induced endothelium-dependent relaxation was not affected by the presence of 10-5 M indomethacin, 10-3 M L-N(G)-nitro-arginine (L-NOARG) or 10-5 M haemoglobin, and was accompanied by accumulation of cGMP but not of cAMP in artery strips. There was a close time-dependent parallel relationship between endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine (10-6 M). The endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine showed much slower kinetics than those induced by ionomycin (10-7 M). Pretreatment of the strips with actinomycin D (10 μg/ml) significantly inhibited not the endothelium-dependent relaxation and accumulation of cGMP induced by ionomycin (10-7 M) but those induced by hydralazine (10-6 M). These results suggest that hydralazine induces endothelium-dependent vasorelaxation via the slow accumulation of cGMP in the strips. This does not occur through the release of nitric oxide or prostaglandin I2 but through immediate transcription and probably expression of a molecule in the endothelium.

AB - Hydralazine relaxed porcine coronary artery strips in a concentration-dependent manner by distinct endothelium-dependent and endothelium-independent actions. With lower doses (≤ 10-6 M), the hydralazine-induced relaxation appears to be completely endothelium-dependent and we designed the present study to elucidate the mechanisms of this endothelium-dependent relaxation. Hydralazine (10-6 M)-induced endothelium-dependent relaxation was not affected by the presence of 10-5 M indomethacin, 10-3 M L-N(G)-nitro-arginine (L-NOARG) or 10-5 M haemoglobin, and was accompanied by accumulation of cGMP but not of cAMP in artery strips. There was a close time-dependent parallel relationship between endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine (10-6 M). The endothelium-dependent relaxation and accumulation of cGMP induced by hydralazine showed much slower kinetics than those induced by ionomycin (10-7 M). Pretreatment of the strips with actinomycin D (10 μg/ml) significantly inhibited not the endothelium-dependent relaxation and accumulation of cGMP induced by ionomycin (10-7 M) but those induced by hydralazine (10-6 M). These results suggest that hydralazine induces endothelium-dependent vasorelaxation via the slow accumulation of cGMP in the strips. This does not occur through the release of nitric oxide or prostaglandin I2 but through immediate transcription and probably expression of a molecule in the endothelium.

KW - cGMP

KW - Endothelium

KW - Hydralazine

KW - Relaxation

UR - http://www.scopus.com/inward/record.url?scp=0031044595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031044595&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(96)00972-7

DO - 10.1016/S0014-2999(96)00972-7

M3 - Article

C2 - 9085042

AN - SCOPUS:0031044595

VL - 321

SP - 307

EP - 314

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -